Dr. Vincenti is professor of clinical medicine at the University of California San Francisco (UCSF).
He has published more than 250 peer-reviewed publications and has been a principal investigator of trials supported by the National Institutes of Health, the Immune Tolerance Network, the UCSF Innovation Ventures Philanthropy Fund (InVent Fund), and industry. His research interests focus on novel biologics, desensitization with novel drugs, and recurrent focal segmental glomerulosclerosis. He has written a series of articles on the complications of transplants and has been a leading investigator on the use of anti-interleukin 2 receptor monoclonal antibodies and costimulation blockade. He is a proponent of minimizing immunosuppressive drugs after transplants.
Dr. Vincenti has been an active member of the American Society of Transplantation (AST), serving as president and on its board of directors and helped establish its Clinical Trials Committee and expanded the collaboration of AST with international transplant societies.
He previously served as associate editor of CJASN and the American Journal of Transplantation and on the editorial board of Transplantation.
Dr. Vincenti received a lifetime achievement award from the AST and was honored by the National Kidney Foundation of Northern California for his contributions to transplantation and treatment of kidney failure.
He completed his medical training, internship, and residency at the American University of Beirut Medical Center in Lebanon. He then did a nephrology fellowship at Emory University School of Medicine in Atlanta, GA. He came to UCSF for a transplant nephrology fellowship and has been on the staff of the kidney transplant service at UCSF since 1976.